Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Abdominal distension? 407 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 407 reports of Abdominal distension have been filed in association with MEPOLIZUMAB (Nucala). This represents 1.0% of all adverse event reports for MEPOLIZUMAB.

407
Reports of Abdominal distension with MEPOLIZUMAB
1.0%
of all MEPOLIZUMAB reports
298
Deaths
346
Hospitalizations

How Dangerous Is Abdominal distension From MEPOLIZUMAB?

Of the 407 reports, 298 (73.2%) resulted in death, 346 (85.0%) required hospitalization, and 298 (73.2%) were considered life-threatening.

Is Abdominal distension Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 407 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Abdominal distension?

ADALIMUMAB (3,728) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (2,238) LEVONORGESTREL (1,700) METHOTREXATE (1,471) TREPROSTINIL (1,437) PREDNISONE (1,429) SEMAGLUTIDE (1,424) VEDOLIZUMAB (1,411) INFLIXIMAB (1,328) POLYETHYLENE GLYCOL 3350 (1,158)

Which MEPOLIZUMAB Alternatives Have Lower Abdominal distension Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Abdominal distension Reports All Drugs Causing Abdominal distension MEPOLIZUMAB Demographics